Literature DB >> 21227742

Versatile binding properties of a di-2-pyridyl ketone nicotinoylhydrazone ligand: crystal structure of a Cu(II) complex.

Neema Ani Mangalam1, M R Prathapachandra Kurup.   

Abstract

Six new copper complexes of di-2-pyridyl ketone nicotinoylhydrazone (HDKN) have been synthesized. The complexes have been characterized by a variety of spectroscopic techniques and the structure of [Cu(DKN)(2)]·H(2)O has been determined by single crystal X-ray diffraction. The compound [Cu(DKN)(2)]·H(2)O crystallized in the monoclinic space group P2(1) and has a distorted octahedral geometry. The IR spectra revealed the presence of variable modes of chelation for the investigated ligand. The EPR spectra of compounds [Cu(2)(DKN)(2)(μ-N(3))(2)] and [Cu(2)(DKN)(2)(μ-NCS)(2)] in polycrystalline state suggest a dimeric structure as they exhibited a half field signal, which indicate the presence of a weak interaction between two Cu(II) ions in these complexes.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21227742     DOI: 10.1016/j.saa.2010.11.032

Source DB:  PubMed          Journal:  Spectrochim Acta A Mol Biomol Spectrosc        ISSN: 1386-1425            Impact factor:   4.098


  3 in total

1.  N'-[(1E)-1-(2-Fluoro-phen-yl)ethyl-idene]pyridine-3-carbohydrazide.

Authors:  P B Sreeja; M Sithambaresan; N Aiswarya; M R Prathapachandra Kurup
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-01-08

2.  N'-[(E)-1-(2-Fluoro-phen-yl)ethyl-idene]pyridine-4-carbohydrazide.

Authors:  P B Sreeja; M Sithambaresan; N Aiswarya; M R Prathapachandra Kurup
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-04-09

3.  Synthesis, Characterization, and In Vivo Anti-Cancer Activity of New Metal Complexes Derived from Isatin-N(4)antipyrinethiosemicarbazone Ligand Against Ehrlich Ascites Carcinoma Cells.

Authors:  Fathy El-Saied; Bishoy El-Aarag; Tarek Salem; Ghada Said; Shaden A M Khalifa; Hesham R El-Seedi
Journal:  Molecules       Date:  2019-09-11       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.